Consensus Alnylam Pharmaceuticals, Inc.

Equities

ALNY

US02043Q1076

Market Closed - Nasdaq 04:30:00 2024-03-18 pm EDT 5-day change 1st Jan Change
147.4 USD -1.25% Intraday chart for Alnylam Pharmaceuticals, Inc. -1.13% -22.99%

Evolution of the average Target Price on Alnylam Pharmaceuticals, Inc.

Price target over the last 5 years

History of analyst recommendation changes

95b137047e763b539fd.kiZPxifUavC2rKT4WDnMSclxBkyKnUzWUUUwyE5JNAQ.9xY8sHOTBKrE2OisaXG9KLs6MSnt1SSXFDNhihckA2D9Hh-ySq4Pk8bd4Q~67b43a104e236690a56ae781191a12e3
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox... Our Logo
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever.... Our Logo
Chardan Cuts Price Target on Alnylam Pharmaceuticals to $225 From $250, Expects Topline Results in Mid-2024, Maintains Buy Rating MT
Goldman Sachs Downgrades Alnylam Pharmaceuticals to Neutral From Buy, Cuts Price Target to $173 From $230 MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia... Our Logo
Wolfe Research Initiates Coverage on Alnylam Pharmaceuticals With Peer Perform Rating MT
Morgan Stanley Adjusts Alnylam Pharmaceuticals' PT to $176 From $184, Keeps Equalweight Rating MT
JPMorgan Adjusts Alnylam Pharmaceuticals' Price Target to $170 From $150, Keeps Neutral Rating MT
RBC Raises Price Target on Alnylam Pharmaceuticals to $235 From $230, Keeps Outperform Rating MT
Wells Fargo Initiates Alnylam Pharmaceuticals With Equalweight Rating, Price Target is $171 MT
Morgan Stanley Adjusts Price Target on Alnylam Pharmaceuticals to $183 From $175, Maintains Equal-Weight Rating MT
RBC Cuts Price Target on Alnylam Pharmaceuticals to $230 From $235, Keeps Outperform Rating MT
UBS Adjusts Alnylam Pharmaceuticals Price Target to $253 From $256, Maintains Buy Rating MT
HC Wainwright Cuts Price Target on Alnylam Pharmaceuticals to $395 From $405, Maintains Buy Rating MT
Oppenheimer Downgrades Alnylam Pharmaceuticals to Perform From Outperform, Removes $249 Price Target MT
RBC Cuts Price Target on Alnylam Pharmaceuticals to $235 From $270 Amid Complete Response Letter, Keeps Outperform Rating MT
Bernstein Cuts Alnylam Pharmaceuticals' Price Target to $218 From $237, Maintains Outperform Rating MT
Evercore ISI Cuts Alnylam Pharmaceuticals' Price Target to $210 From $252, Maintains Outperform Rating MT
TD Cowen Adjusts Alnylam Pharmaceuticals' Price Target to $260 From $265, Maintains Outperform Rating MT
Morgan Stanley Cuts Alnylam Pharmaceuticals' Price Target to $175 From $210, Keeps Equalweight Rating MT
BMO Capital Cuts Price Target on Alnylam Pharmaceuticals to $234 From $250, Maintains Outperform Rating MT
Earnings season starts with PepsiCo Our Logo
Earnings season starts with PepsiCo Our Logo
Citigroup Adjusts Alnylam Pharmaceuticals' Price Target to $233 From $266, Keeps Buy Rating MT
ANALYST RECOMMENDATIONS : Dollar General, Estee Lauder, ResMed, Tesla, Ulta Beauty... Our Logo
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
147.4 USD
Average target price
220.8 USD
Spread / Average Target
+49.76%
High Price Target
395 USD
Spread / Highest target
+167.96%
Low Price Target
136 USD
Spread / Lowest Target
-7.74%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Alnylam Pharmaceuticals, Inc.

Chardan Research
Goldman Sachs
Wolfe Research
Morgan Stanley
JPMorgan Chase
RBC Capital Markets
Wells Fargo Securities
UBS
HC Wainwright
Oppenheimer
Bernstein
Evercore ISI
TD Cowen
BMO Capital
Citigroup
Needham & Co.
Raymond James
Canaccord Genuity
EF Hutton
SVB Securities LLC
Piper Sandler
Berenberg Bank
Jefferies & Co.
Cantor Fitzgerald
Guggenheim
William Blair & Co.
SVB Leerink
Stifel Nicolaus
Chardan
Barclays
Cowen
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings